# MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD

> **NCT02876172** · PHASE1,PHASE2 · COMPLETED · sponsor: **Resilient Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Posttraumatic Stress Disorder

## Interventions

- **DRUG:** MDMA
- **BEHAVIORAL:** CBCT
- **BEHAVIORAL:** Therapy

## Key facts

- **NCT ID:** NCT02876172
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-03
- **Primary completion:** 2017-12-16
- **Final completion:** 2018-05-29
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876172, "MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02876172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*